

LINCOLN PHARMACEUTICALS LIMITED

Regd. Office: "LINCOLN HOUSE", B/H. SATYAM COMPLEX, SCIENCE CITY ROAD, SOLA, AHMEDABAD-380 060.
Tel. No. :- 079-67778000, Fax. No.-079-67778062. email id: info@lincolnpharma.com., CIN-L24230GJ1995PLC024288

AUDITED FINANCIAL RESULTS FOR THE QUARTER/YEAR ENDED ON 31.03.2015

(Rs.in Lacs.)

PART - I PARTICULARS	CONSOLIDATED					STANDALONE				
	QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED			
	31.03.2015 (Audited)	31.12.2014 (Un-Audited)	31.03.2014 (Audited)	31.03.2015 (Audited)	31.03.2014 (Audited)	31.12.2014 (Un-Audited)	31.03.2014 (Audited)	31.03.2015 (Audited)	31.03.2014 (Audited)	31.03.2014 (Audited)
1 Income from operations										
(a) Net Sales/income from operation (Net of excise duty)	7869.83	6451.58	6478.85	26607.45	21126.69	6228.94	5670.47	6186.01	22325.99	20849.02
(b) Other operating income	-13.23	301.45	196.85	718.56	171.61	-111.06	259.08	129.22	533.80	142.33
Total income from operations (net)	7856.60	6753.03	6675.70	27326.01	21298.30	6117.88	5929.55	6315.23	22859.79	20991.35
2 Expenses										
(a) Cost of materials consumed	1244.20	1213.99	2081.01	5377.70	5302.06	953.88	1088.57	1472.20	4349.74	4125.27
(b) Purchases of stock-in-trade	4088.51	3151.80	2734.60	12307.98	8989.80	2804.04	2738.20	3267.05	9814.62	10578.20
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	295.24	99.17	38.22	270.55	-314.09	263.26	65.25	61.84	193.49	-209.31
(d) Employee benefits expense	442.99	472.20	471.76	1787.09	1894.71	394.34	419.59	405.64	1585.43	1618.77
(e) Depreciation and amortisation expense	101.18	112.31	87.88	456.81	352.65	59.76	71.00	57.09	293.01	227.94
(f) Other expenses	1056.65	1181.28	814.13	4303.57	3169.05	1126.70	1057.50	728.47	4072.06	2865.74
Total expenses	7228.77	6230.75	6227.60	24503.70	19394.18	5601.98	5440.11	5992.29	20308.35	19206.61
3 Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	627.83	522.28	448.10	2822.31	1904.12	515.90	489.44	322.94	2551.44	1784.74
4 Other income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items(3+ 4)	627.83	522.28	448.10	2822.31	1904.12	515.90	489.44	322.94	2551.44	1784.74
6 Finance costs	289.33	170.78	312.18	837.74	696.99	227.50	120.47	225.92	634.74	530.33
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items(5 - 6)	338.50	351.50	135.92	1984.57	1207.13	288.40	368.97	97.02	1916.70	1254.41
8 Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	338.50	351.50	135.92	1984.57	1207.13	288.40	368.97	97.02	1916.70	1254.41
10 Tax expense	115.44	99.64	58.58	480.43	188.67	97.11	88.55	39.14	439.40	111.65
11 Net Profit / (Loss) from ordinary activities after tax (9 - 10)	223.06	251.86	77.34	1504.14	1018.46	191.29	280.42	57.88	1477.30	1142.76
12 Extraordinary items (net of tax expense)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
13 Net Profit / (Loss) for the period (11 - 12)	223.06	251.86	77.34	1504.14	1018.46	191.29	280.42	57.88	1477.30	1142.76
14 Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority interest *	2.94	-7.11	7.67	2.93	-46.96	0.00	0.00	0.00	0.00	0.00
16 Net Profit / (Loss) after taxes, minority interest and shares of profit/(loss) of associates ((13 - (14 +15)) *	220.12	258.97	69.67	1501.21	1066.42	191.29	280.42	57.88	1477.30	1142.76
17 Paid-up equity share capital of face value Rs.10/- each	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08	1631.08
18 Reserve excluding Revaluation Reserves as per balance sheet of previous a/c. year	-----	-----	-----	9500.04	8250.16	-----	-----	-----	9503.53	8281.66
19 i a) Basic and diluted EPS before Extraordinary items(f.v.10/- each) and Prior period Adjustment.(Not Annualised)	1.35	1.59	0.43	9.20	6.53	1.17	1.72	0.35	9.06	7.01
19 ii b) Basic and diluted EPS after Extraordinary items (f.v.10/- each) and Prior period Adjustment.(Not Annualised)	1.35	1.59	0.43	9.20	6.53	1.17	1.72	0.35	9.06	7.01

PART - II										
A PARTICULARS OF SHAREHOLDING										
1 Public Shareholding:										
- Number of shares	10350573	11001573	10979649	10350573	10979649	10350573	11001573	10979649	10350573	10979649
- Percentage of Shareholding	63.46	67.45	67.32	63.46	67.32	63.46	67.45	67.32	63.46	67.32
2 Promoters and Promoter group Shareholding:										
a) Pledged/Encumbered										
- Number of shares	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of Shareholding (as a %of the total share capital of the Company)	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-encumbered										
- Number of shares	5960227	5309227	5331151	5960227	5331151	5960227	5309227	5331151	5960227	5331151
- Percentage of Shareholding (as a %of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shareholding (as a %of the total share capital of the Company)	36.54	32.55	32.68	36.54	32.68	36.54	32.55	32.68	36.54	32.68
Particulars	Qtr. Ended on 31.03.15									
B INVESTOR COMPLAINTS										
Pending at the beginning of the quarter	NIL									
Received during the quarter	1									
Disposed of during the quarter	1									
Remaining unresolved at the end of the quarter	NIL									

NOTES:-

- The above results were reviewed by the audit committee and approved by the Board of Directors at its meeting held on 30.05.2015.
- The Board has recommended the payment of Dividend of Rs.1.00 (@ 10%) per equity share of f.v.Rs.10/- each of the Company.
- Previous year figures are regrouped/reclassified to confirm to the current year's presentation.
- The Company has Allotted 36,89,200 warrants convertible in to equal number of equity shares of Rs.10/- each on preferential basis at price 82/- per share(which includes premium of Rs.72/-per share) to the promoters/promoters' groups and person other than the promoters/promoters' groups pursuant to the SEBI (ICDR) Regulation,2009.
- Figures of last quarter are the balancing figures between audited figures in respect of financial year and unaudited published year to date figures upto third quarter of the financial year.
- Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- Consolidated results includes results of its two subsidiary Company.
- 8. Statement of Assets and Liabilities are as under:**

Particulars	Consolidated		Standalone	
	As at 31.03.15 (Audited)	As at 31.03.14 (Audited)	As at 31.03.15 (Audited)	As at 31.03.14 (Audited)
A EQUITY AND LIABILITIES				
1 Shareholders' Fund				
(a) Share Capital	1631.08	1631.08	1631.08	1631.08
(b) Reserves and Surplus	9500.04	8250.16	9503.53	8281.67
(c) Money received against share warrants	0	0	0	0
Sub-total - Shareholders' funds	11131.12	9881.24	11134.61	9912.75
2 Share Application money/pending allotment	0	0	0	0
3 Minority interest	292.63	370.54	0	0
4 Non-Current Liabilities				
(a) Long term borrowings	2547.94	1923.54	43.51	259.34
(b) Deferred tax liabilities(net)	463.58	397.48	304.87	266.23
(c) Other long-term liabilities	302.30	297.43	302.3	297.43
(d) Long-term provisions	0	0	0	0
Sub-total - Non-Current Liabilities	3606.45	2988.99	650.68	823.00
5 Current Liabilities				
(a) Short term borrowings	5467.40	4846.46	5164.90	4801.22
(b) Trade Payable	4530.82	6651.00	1329.30	5020.25
(c) Other Current liabilities	1349.32	1530	1278.82	1367.99
(d) Short term provisions	35.01	0	35.01	14.36
Sub-total - Current Liabilities	11382.55	13027.46	7808.03	11203.82
TOTAL - EQUITY AND LIABILITIES	26120.12	25897.69	19593.32	21939.57
B ASSETS				
1 Non-Current Assets				
(a) Fixed assets	6336.68	6330.18	3585.15	3474.32
(b) Goodwill on consolidation	458.83	414.30	0	0
(c) Non-current investments	21.79	40.57	1263.67	1121.20
(d) Deferred tax assets(net)	0	0	0	0
(e) Long-term loans and advances	1174.83	4169.20	1190.06	1059.43
(f) Other non-currents assets	19.37	0	0	0
Sub-total - Non-Current assets	8011.50	10954.25	6038.88	5654.95
2 Current Assets				
(a) Current investments	0	0	0	0
(b) Inventories	2181.84	2384.10	1928.48	2083.98
(c) Trade Receivables	12198.17	8823.18	8631.07	8623.64
(d) Cash and cash equivalents	386.6	497.03	346.72	459.09
(e) Short-term loans and advances	2577.67	2691.02	2375.78	4831.56
(f) Other current assets	764.34	548.11	272.39	286.35
Sub-total - Current assets	18108.62	14943.44	13554.44	16284.62
TOTAL - ASSETS	26120.12	25897.69	19593.32	21939.57

Place : Ahmedabad.
Date : 30.05.2015

For LINCOLN PHARMACEUTICALS LIMITED

sd/-
(Mahendra G. Patel)
Managing Director